(COMTEX) B: DNAPrint genomics Partners With GeneLink to Develop 'Next Ge
B: DNAPrint genomics Partners With GeneLink to Develop 'Next Generation'
Genetic-Profile Tests for Personalized Cosmetics
SARASOTA, Fla., Mar 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- DNAPrint (OTC
Bulletin Board: DNAP) (the "Company"), the world leader in the measurement of
population structure for disease genetics, personalized medicine, recreational
genomics and forensics profiling, announced today that it has entered into a
collaborative agreement with GeneLink (OTC Bulletin Board: GNLK) to develop new
genetic assessments for a personalization of cosmetics and personal care product
marketing. The agreement also names DNAPrint as GeneLink's genotyping partner.
Further details were not disclosed.
The parties intend to develop tests that will be used to assess genetic risks
for certain common skin deficiencies. The test results are expected to provide a
basis for recommending formulations that have been specifically designed to
compensate for these deficiencies. Rather than merely marketing a genetic test,
DNAPrint will assist GeneLink and its partners, which include Arch Chemical
(http://www.bankdna.com/news_articles/02_11_03.asp ), in focusing on offering a
preventative solution for certain common dermatological and skin aging problems.
The system would be marketed as part of an individualized precautionary health
regimen, and offered for sale by distributors and manufactures to the $100
billion plus cosmetics and personal care industry.
DNAPrint's brings its ultra high throughput genotype capability and ADMIXMAP
platform to the partnership while GeneLink brings existing tests and
methodologies. The companies intend to screen millions of candidate markers and
broaden proprietary product offerings.
About the test
Through the expression of certain genes, skin defends itself from photo- aging
and from oxidative stress that is caused by certain common, potentially harmful
molecules known as free radicals. Other genetic defense measures catalyze the
detoxification of certain harmful environmental pollutants and some actually
cause mild irritation that results from exposure to common products used in
daily living (such as soaps). Though all humans have built-in genetic defense
mechanisms, the skin for some people is more adept at certain defenses than for
others, and this variability in defensive capability is rooted in the genes.
GeneLink's Dermagenetics(TM) assessment measures these genes for individual
customers by reading key gene variant sequences called Single Nucleotide
Polymorphisms (SNPs). The SNPs are known from decades of public and privately
funded research to be associated with accelerated skin aging, skin wrinkling and
other specific oxidative stress deficiencies in the skin
About GeneLink
GeneLink, Inc., a pioneer DNA banking and hereditary genetic information
service, has developed a proprietary method for genetic assessments (patents
pending) and is beginning to license its breakthrough Nutragenetic and
Dermagenetic Profile Assessments(TM) to companies that market or manufacture
products for the $100 billion plus skin care, nutritional supplement, and health
care industries. For more information about GeneLink, visit its Web site at
www.genelink.info . For more information on Dermagenetics testing, see the
article "Designer Cosmetics" in the Business Journal, March 25, 2002 (80(12) p.
16-21.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. was founded by a team of scientists with research and
commercial experience in high-level mathematical modeling, programming and
molecular genetics. Using proprietary human genome research methods, the Company
develops chemopredictive tests for matching patients with drugs based on their
genetic constitution, discovers disease genes for the development of new drugs
and develops new forensic genomics and recreational genomics testing products.
The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol:
DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities Exchange
Act as amended. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected, including,
but not limited to, uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's products,
dependence on collaborations and partners, regulatory approvals, competition,
intellectual property of others, and patent protection and litigation. DNAPrint
genomics, Inc. expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements
are based.
Contacts
Phil Brooks John R. DePhillipo, Chairman/CEO
DNAPrint genomics, Inc. GeneLink, Inc.
Director, Marketing Communications 609-823-6991
(941) 366-3400 email: genelink@aol.com
PBrooks@AncestrybyDNA.Com www.genelink.info
www.DNAPrint.com
SOURCE DNAPrint genomics, Inc.
CONTACT: Phil Brooks Director, Marketing Communications of DNAPrint
genomics, Inc., +1-941-366-3400, or PBrooks@AncestrybyDNA.com
DePhillipo, Chairman and CEO of GeneLink, Inc., +1-609-823-69
genelink@aol.com
URL: dnaprint.com
CGR |
